GlassScriptPhysician profile
Ramin Rabbani
NPI 1518962539
$6,349.81
in general payments reported to CMS, 2019-2025
31 companies · $907 in 2025
The $907 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $772 · 2021: $892 · 2022: $1,080 · 2023: $986 · 2024: $793 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,608 · Education: $77.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.19 |
| Education | $77.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $941.62 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $917.80 | 2019-2024 | Xarelto |
| Amgen INC. | $760.84 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $456.59 | 2019-2025 | Camzyos, Abilify, Eliquis |
| Biotronik INC. | $407.96 | 2019-2023 | Biomonitor |
| Astrazeneca Pharmaceuticals LP | $404.40 | 2019-2024 | Farxiga |
| Pfizer INC. | $334.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.91 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $239.91 | 2019-2023 | |
| Boston Scientific Corporation | $208.30 | 2019-2025 | Watchman Flx, Watchman Access System |
| Alnylam Pharmaceuticals INC. | $202.84 | 2022-2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $180.42 | 2022 | |
| Merck Sharp & Dohme LLC | $147.26 | 2021-2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $134.56 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $93.92 | 2022-2023 | Arcalyst |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $59.53 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Esperion Therapeutics, INC. | $56.71 | 2020-2025 | Nexletol |
| Philips North America LLC | $54.71 | 2022-2025 | Igt Devices Systems Undivided |
| Amarin Pharma, INC. | $52.82 | 2020-2022 | |
| Bridgebio Pharma, INC. | $52.77 | 2025 | Attruby |
| Medtronic, INC. | $46.94 | 2021-2022 | |
| Abbott Laboratories | $45.00 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $44.27 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $39.91 | 2025 | Assure Wcd |
| Atricure, INC. | $37.84 | 2023 | |
| Cleerly, INC. | $32.11 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Celgene Corporation | $23.80 | 2023 | Eliquis |
| Sun Pharmaceutical Industries INC. | $16.05 | 2021 | |
| Coala Life INC | $13.84 | 2022 | |
| Medtronic Vascular, INC. | $12.87 | 2019 | |
| Globus Medical, INC. | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Rabbani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.